Cardiac Myosin Inhibitor

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM and Complementary Trials

By MedXY 09/09/2026

Aficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.

Cardiology news

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

By MedXY 06/28/2026

The FOREST-HCM long-term study confirms aficamten's efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.

Cardiology Specialties

Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy

By MedXY 09/10/2025

A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).

Cardiology Clinical Updates news Specialties

Aficamten: A Breakthrough Oral Therapy for Obstructive Hypertrophic Cardiomyopathy Across Symptom Severity

By MedXY 08/17/2025

Aficamten significantly improves exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM), demonstrating robust efficacy and safety in both mildly and severely symptomatic patients.